<DOC>
	<DOCNO>NCT00567879</DOCNO>
	<brief_summary>The primary purpose study identify maximum tolerate dose ( MTD ) intravenous oral panobinostat plus trastuzumab . The study evaluate safety efficacy combination adult female patient HER2+ metastatic breast cancer</brief_summary>
	<brief_title>A Trial Panobinostat Trastuzumab Adult Female Patients With HER2 Positive Metastatic Breast Cancer ( MBC ) Whose Disease Has Progressed After Trastuzumab</brief_title>
	<detailed_description>This phase Ib/IIa study prematurely terminate due lack efficacy note 55 patient HER2-positive MBC progress follow trastuzumab-based therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Key Inclusion criterion : Age &gt; 18 year old Confirmed HER2+ metastatic breast cancer Prior treatment progression trastuzumab Patients must adequate laboratory value Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Key Exclusion criterion : Patients active central nervous system ( CNS ) disease brain metastasis except previously treat stable least 3 month . Impaired heart function clinically significant heart disease Impairment gastrointestinal ( GI ) function , GI disease may significantly alter absorption LBH589 Ongoing diarrhea Liver renal disease impair hepatic renal function Concomitant use anticancer therapy certain drug Female patient pregnant breast feed Patients willing use effective method birth control</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>adult-female</keyword>
	<keyword>LBH589</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>panobinostat</keyword>
</DOC>